Drug intelligence / Profile preview

Mecozit-OD

Development stage: Unknown
Lead developer: Sycon Healthcare
Modality: Small Molecules
Administration: Oral

Overview

Mecozit-OD is an oral multivitamin and mineral supplement developed and marketed by Sycon Healthcare. It is formulated as a once-daily capsule containing a combination of methylcobalamin (Vitamin B12), alpha lipoic acid, pyridoxine (Vitamin B6), folic acid (Vitamin B9), benfotiamine, biotin, and chromium. Mecozit-OD is primarily indicated for the management of diabetic neuropathy, peripheral neuropathy, megaloblastic anemia, and general vitamin B12 deficiencies. The active ingredients work synergistically to support nerve regeneration, reduce oxidative stress, promote red blood cell formation, and maintain healthy cellular metabolism.

Brand names: Mecozit-OD
Other names: Mecozit-OD CapsuleMecozit-OD Capsules

Targets

MTR (Methionine synthase)TKT (Transketolase)DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on Mecozit-OD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mecozit-OD.

Explore the full profile